Quote & Headlines
Market Currents
StockTalk
Description
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
322 people get SCMP articles and Market Currents by email alert.
Get email alerts on SCMP »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (May 15, 2013)
-
Business Wire (May 13, 2013)
-
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 30, 2013)
-
-
Business Wire (Mar 29, 2013)
-
-
-
Business Wire (Mar 13, 2013)
-
Business Wire (Mar 1, 2013)
-
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 8, 2013)
-
Business Wire (Feb 6, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
Life Sciences Companies Raise Record Amounts of CapitalThe Burrill Report • Fri, Dec 31, 2010 -
-
-
-
How ROE Shows Which Companies are Undervalued in an IndustryMagicDiligence • Wed, May 20, 2009 -
-
-
-
Pharmaceutical IPO: Sucampo Inc. Files S-1 (SCMP)SA Editor Abbi Adest • Fri, Jun 23, 2006
-
Sucampo Pharmaceuticals, Inc.Q2 2009 Earnings Call TranscriptThu, Aug 6, 2009
-
Sucampo Pharmaceuticals, Inc. Q1 2009 Earnings Call TranscriptFri, May 8, 2009
-
Sucampo Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptThu, Feb 19, 2009
-
Sucampo Pharmaceuticals Inc. Q3 2008 Earnings Call TranscriptWed, Nov 12, 2008
-
Sucampo Pharmaceuticals, Inc. Q2 2008 Earnings Call TranscriptMon, Aug 18, 2008
-
Sucampo Pharmaceuticals Inc. Q1 2008 Earnings Call TranscriptMon, May 26, 2008
-
Business Wire (May 15, 2013)
-
Business Wire (May 13, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 30, 2013)
-
Business Wire (Mar 29, 2013)
-
Business Wire (Mar 13, 2013)
-
Business Wire (Mar 1, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 8, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Feb 4, 2013)
-
Business Wire (Jan 3, 2013)
-
Business Wire (Dec 12, 2012)
-
Business Wire (Dec 11, 2012)
-
Business Wire (Nov 30, 2012)
-
Business Wire (Nov 26, 2012)
-
Business Wire (Nov 8, 2012)
SCMP vs. ETF Alternatives
Company Description
Currently, there's no company description for SCMP.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 7, 8:02 PM Sucampo (SCMP): Q1 EPS of -$0.08 in-line. Revenue of $16.9M misses by $0.41M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, April 23, 8:07 AM Sucampo Pharmaceuticals (SCMP) and its partner Takeda (TKPHF.PK) say AMITIZA has racked up a third indication as the FDA approves the drug for the treatment of opioid-induced constipation. Cantor Fitzgerald previously said AMITIZA could ultimately prove to be a major catalyst for shares of SCMP which are up a quick 13.6% premarket. 1 Comment [Healthcare, On the Move]
- Wednesday, April 3, 11:42 AM Sucampo Pharmaceuticals (SCMP +6.6%) climbs higher after Cantor Fitzgerald says excitement surrounding the opioid-induced constipation drug Amitiza "could significantly rally the stock" in the short-term. Additionally, the company's partnership with Takeda (TKPHF.PK +3.4%) makes for a compelling long-term story. SCMP is initiated at Buy with a $9 price target. Comment! [Healthcare]
- Tuesday, March 19, 10:42 AM Sucampo Pharmaceuticals (SCMP +6%) gets a boost this morning from Maxim initiating the shares with a Buy rating and a price target of $10. The stock actually began trending higher last week after TheStreet.com mentioned it as one of five sub-$10 stocks that are triggering technical breakouts. Comment! [Healthcare, On the Move]
- Wednesday, March 13, 5:23 PM Sucampo (SCMP): Q4 EPS of $0.32. Revenue of $34.9M beats by $2.7M. Shares -0.8% AH. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, February 4, 10:37 AM Sucampo (SCMP +0.6%) bucks a weak tape after saying that the Japanese Science and Technology Agency has adopted the company's unoprostone isopropyl ophthalmic solution into its Technology Transfer Program. As part of the program, Japanese development partner R-Tech Ueno has signed an agreement with the agency to provide the majority of funding for Phase 3 clinical development costs for its treatment of retinitis pigmentosa. SCMP is planning to file for FDA approval pending the successful trials. Comment! [Healthcare, Global & FX]
- Wednesday, December 12, 2012, 12:13 PM Sucampo Pharmaceuticals (SCMP +4.2%) moves higher today after earlier announcing its supplemental new drug application for Rescula, a treatment for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, has been approved by the FDA. According to the labeling, the treatment may be used as a first-line agent or in tandem with other topical ophthalmic drugs. Comment! [Healthcare, On the Move]
- Wednesday, December 12, 2012, 9:56 AM Sucampo Pharma's (SCMP +6.1%) supplemental new drug application for its Rescula treatment to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension receives approval from the FDA. SCMP says it intends to commercialize the drug in Q1 2013. Comment! [Healthcare, On the Move]
-
Wednesday, December 12, 2012, 9:10 AM
Premarket gainers: YMI +79%. DSTI +15%. SCMP +11%. ACAD +9%. BGMD +10%.
Losers: RSOL -16%. CIE -11%. MCP -6%. Comment! [On the Move] - Tuesday, December 4, 2012, 12:59 PM Shares of Sucampo Pharmaceuticals (SCMP -4.4%) extend yesterday's slide on the back of the FDA's reveiw extension of the company's Amitiza drug to treat opioid-induced constipation in patients with chronic, noncancer pain. Comment! [Healthcare, On the Move]
- Monday, December 3, 2012, 8:42 AM Sucampo Pharmaceuticals (SCMP) -8.4% premarket after announcing Friday the FDA extended by three months its review of the company's Amitiza drug to treat opioid-induced constipation in patients with chronic, non-cancer pain. The FDA decides to extend the goal date to provide time for a full review of supportive analyses it had requested. 1 Comment [Healthcare, On the Move]
-
Friday, November 30, 2012, 5:46 PM
After-hours top gainers, as of 5:15 p.m.: NTLS +25.2%. GAI +10.2%. CBE +5.8%. GEO +5.4%. SYRG +2.8%.
After-hours top losers: SCMP -8.4%. CDXS -3.3%. JRCC -2.9%. BKW -2.8%. GFIG -2.7%. 1 Comment [On the Move] - Monday, November 26, 2012, 12:57 PM Sucampo Pharmaceuticals (SCMP -0.8%) and Abbott (ABT -0.6%) launch Amitiza, a prescription medicine for the treatment of chronic constipation, in Japan. The drug was approved by the Japanese Ministry of Health, Labor and Welfare in Japan in June. ABT will promote and distribute Amitiza in Japan under the terms of a 2009 license agreement with SCMP. Comment! [Healthcare, Global & FX]
-
Wednesday, September 26, 2012, 12:45 PM
Midday top 10 gainers: LPHI +112%. CTC +18%. AM +17%. STSI +15%. KCG +11%. WCBO +11%. CAMP +10%. DIAL +10%. SCMP +10%. SVN +8%.
Top 10 Losers: PATH -27%. BTH -19%. OMN -14%. RMKR -13%. CPRX -13%. TISA -12%. GEVO -12%. MITK -12%. OINK -12%. TSTC -11%. Comment! [On the Move] -
Wednesday, September 26, 2012, 9:10 AM
Premarket gainers: SCMP +13%.
Losers: PATH -32%. BTH -24%. CPRX -20%. GEVO -12%. FTNT -7%. JBL -6%. GTAT -6%. Comment! [On the Move] - Tuesday, September 25, 2012, 4:42 PM Sucampo Pharmaceuticals (SCMP) and Takeda Pharmaceuticals (TKPYY.PK) say the FDA,has granted priority review of their supplemental new drug application for an additional indication for Amitiza, a treatment for opioid-induced constipation in patients with chronic, non-cancer pain. A decision is expected by late January 2013. Shares +7% AH. Comment! [Healthcare, On the Move]
-
Ryan Mallory
Fuinhaz Setups for April 23 2013 | $AAPL $AMRN $ARMH $MCGC $NFLX $NXPI $SCMP $VECO | SharePlanner http://bit.ly/10aXrHM - View all 0 replies
-
Red Acre Investments
just published part 1 of our April Biotech binary event watch : http://bit.ly/ZmquIg $AGN, $THRX, $ENDP, $SCMP, $GILD - View all 0 replies
-
- View all 0 replies
-
Scott Matusow
I think $SCMP makes a move to $6.50 next week, afterwards, might pull back then a run to $7.50+ into January - View all 5 replies
-
-
-
Scott Matusow
$SCMP 72M in cash, burns 1.2M per CTL, revenue of 53M catalyst play + undervalued per market cap - View all 0 replies
-
Scott Matusow
$SCMP AMITIZA treatment of opioid-induced constipation patients with chronic, non-cancer pain. FDA decision expected on 1/27/13. 250M - View all 0 replies
-
Scott Matusow
$SCMP, article soon on $SCMP. 2 catalysts, strong cash position, low burn, 250M potential revenue, 270M market cap - View all 0 replies
-
Scott Matusow
I bought $SCMP and alerted I think before others. Nice run up potential, looking for $7.50 by Jan. - View all 0 replies
-
Jim Van Meerten
SCMP - 40% Barchart.com technical sell signal-13.89% off recent high-Relative Strength Index 42.85% and falling - View all 0 replies
-
Jim Van Meerten
SCMP -- Sucampo Pharmaceuticals - 100% Barchart buy signal-16 new highs and up 21.01% in the last month - Relative Strength Index - 85.95%+ - View all 0 replies
LATEST REPLIES
-
Scott Matusow
I think $SCMP makes a move to $6.50 next week, afterwards, might pull back then a run to $7.50+ into January - View all 5 replies
-
-